The treatment of patients with RARS involves supportive care strategies and includes ESAs, transfusions, and iron chelation. In this activity, Dr. Navada outlines the appropriate treatment strategies.

In this activity, Dr. Shyamala Navada describes refractory anemia with ring sideroblasts and what this presence means for your patient with MDS.

Join Dr. David Sallman as he gives an exciting update regarding the potential pipeline in MDS.

In this activity, Dr. Padron discusses patients developing iron overload after receiving a red blood cell transfusion and the current standard of care to minimize the consequences of this occurrence.

In this activity, Dr. Padron discusses the positive activity of luspatercept in clinical trials with low-risk MDS and where this may be an appropriate option.

Dr. Park outlines the importance of assessment for IDH mutations in your patients with MDS, as the presence of these mutations significantly impacts prognosis.

Dr. Park summarizes the use of IDH1/2 inhibitors in the AML setting and how this treatment may apply to your patients with MDS.

Dr. Park discusses the factors that influence whether a patient's MDS will transform to AML, and how to identify those factors in your patient.

Dr. Park provides a brief overview of the commonality of IDH mutations in MDS vs. AML.

In this short video, Dr. Wang reviews how you can evaluate whether it's time to stop HMA therapy and if so, what to do next.